Justification, safety, and efficacy of a third dose of mRNA

vaccine in maintenance hemodialysis patients:

a prospective observational study

Maxime Espi<sup>1,2\*</sup>, Xavier Charmetant<sup>1\*</sup>, Thomas Barba<sup>1,3,4</sup>, Caroline Pelletier<sup>5</sup>, Laetitia Koppe<sup>2,4</sup>, Elodie Chalencon<sup>2</sup>, Emilie Kalbacher<sup>5</sup>, Virginie Mathias<sup>1,6</sup>, Anne Ovize<sup>7</sup>,

Emmanuelle Cart-Tanneur<sup>7</sup>, Christine Bouz<sup>7</sup>, Laurence Pellegrina<sup>7</sup>, Emmanuel

Morelon<sup>4,8</sup>, Laurent Juillard<sup>4,5</sup>, Denis Fouque<sup>2,4</sup>, Cécile Couchoud<sup>9,10</sup>, Olivier

Thaunat<sup>1,4,8,#</sup>

List of collaborators from the REIN registry: Chantrel François, Reydit Mathilde,

Tiple Aurélien, Bechade Clémence, Bemrah Abdelkader, Vigneau Cécile, Sautenent

Bénédicte, Kazes Isabelle, Courivaud Cécile, Gabriel Jean-Marc, Edet Stéphane,

Mercadal Lucile, Moranne Olivier, Toure Fatouma, Laurain Emmanuelle, Ranlin Alex,

Longlune Nathalie, Glowacki François, Tivollier Jean-Michel, Brunet Philippe,

Lavainne Fréderic, Berard Etienne, Sarraj Ayman, Bauwens Marc, Testevuide

Pascale, Vacher Coponat Henri, Galland Roula, Schauder Nicole, Salmi Louis -

Rachid, Cerasuolo Damiano, Tendron-Franzin Anaïs, Bayat Sahar, Halimi Jean

Michel, Wolak Aurore, Gentile Stéphanie, Devictor Bénédicte, Monnet Elisabeth,

Boucaut Maitre Denis, Nacher Mathieu, Merle Véronique, Jais Jean-Philippe, Daures

Jean-Pierre, Vergnenegre Alain, Loos-Ayav Carole, Merle Sylvie, Hazzan Marc,

Gervolino Shirley, Nguyen Jean-Michel, Iacobelli Silvia

- \* equal contribution
- 1) CIRI, INSERM U1111, Université Claude Bernard Lyon I, CNRS UMR5308, Ecole Normale Supérieure de Lyon, Univ. Lyon, 21 avenue Tony Garnier, 69007 Lyon, France.
- 2) Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Department of nephrology, nutrition and hemodialysis, 163 avenue du grand Revoyet, 69310 Pierre-Bénite, France.
- 3) Hospices Civils de Lyon, Edouard Herriot Hospital, Department of internal medicine, 5, place d'Arsonval, 69003 Lyon, France
- 4) Claude Bernard University (Lyon 1), 43 boulevard du 11 Novembre 1918, 69622 Villeurbanne France.
- 5) Hospices Civils de Lyon, Edouard Herriot Hospital, Department of nephrology, 5 place d'Arsonval, 69003 Lyon, France.
- 6) Human Leukocyte Antigen (HLA) Laboratory, French National Blood Service (EFS), 69150 Décines-Charpieu, France
- 7) Eurofins Biomnis Laboratory, 69007 Lyon, France
- 8) Hospices Civils de Lyon, Edouard Herriot Hospital, Department of Transplantation, Nephrology and Clinical Immunology, 5, place d'Arsonval, 69003 Lyon, France.
- 9) REIN registry, Agence de la biomédecine, Saint-Denis La Plaine, France
- Université Lyon I, CNRS, UMR 5558, Laboratoire de Biométrie et Biologie
   Evolutive, Equipe Biostatistique Santé, Villeurbanne France

## # Correspondence to:

Olivier Thaunat MD, PhD

Service de Transplantation, Néphrologie et Immunologie Clinique,

Hôpital Edouard Herriot, 5 Place d'Arsonval, 69003 Lyon, France

Phone: +33 472110170

Email: olivier.thaunat@chu-lyon.fr

Key-words: Hemodialysis, COVID-19, SARS-Cov-2, mRNA vaccine, BNT162b2

Word count: 3258; Figures: 4; Tables: 3

Abstract (271 words)

Background: Patients on maintenance hemodialysis (MHD) are at high risk of

infection with SARS-Cov-2 and death due to COVID-19. This vulnerable population

has been prioritized for vaccination, but the level of protection achieved in these

immunocompromised patients is unclear.

Objectives: To evaluate the protection of MHD patients against COVID-19 after 2

doses (2D) of BNT162b2, and the safety and impact on immune responses of a 3rd

dose (3D).

**Design:** Prospective observational.

Setting, Patients, intervention and measurements: REIN national registry was used

to compare the severity of 1474 cases of COVID-19 diagnosed in MHD patients after

0, 1 or 2 doses of mRNA vaccine. Anti-spike receptor binding domain (RBD) IgG and

interferon gamma-producing CD4+ and CD8+ specific-T cells were measured after 2D

and 3D of BNT162b2 in a monocentric cohort of 75 MHD patients.

Results: Vaccination reduced disease severity but 11% of MHD patients infected after

2D still died. Tolerance to 3D of BNT162b2 was excellent. MHD patients with humoral

response similar to healthy volunteers after 2D did not generate more immune

effectors after 3D and had more side effects. In contrast, 2/3 of MHD patients with

suboptimal response after 2D reached optimal titer of anti-RBD IgG and/or developed

spike-specific CD8+ T cells after 3D. Presence of spike-specific CD4+ T cells after 2D

was associated with response to 3D in multivariate analysis (OR=4.80 [1.23-21.54];

p=0.029).

4

**Limitations:** Limited number of patients injected with 3D.

Conclusion: Standard scheme of vaccination provides insufficient protection to some

MHD patients. Anti-RBD IgG and specific CD4+ T cells should be measured after 2D.

Among patients with suboptimal humoral response, those with specific CD4+ T cells

could benefit of a 3<sup>rd</sup> dose of vaccine.

☐ *Registration:* NCT04881396

5

☐ *Funding Source:* None

Introduction

Among the various alarms raised by the COVID-19 pandemic was its impact on the

population of patient with end stage renal disease (1,2), particularly those requiring in

center hemodialysis. The logistical aspects of the technique indeed increase the risk

of SARS-Cov-2 infections (3), which on the highly co-morbid profile of MHD patients

then translates into a high rate of COVID-19-related death (1,4–6).

Aiming at protecting this vulnerable population, French health authorities prioritized

MHD patients for vaccination (7). However, while two doses (2D) administered

intramuscularly three weeks apart of BNT162b2, a lipid nanoparticle-encapsulated

mRNA-based vaccine, induced both strong humoral and cellular immune responses

against the spike protein of SARS-CoV-2 in the general population (8), our group (9)

and others (10-14) have recently reported that MHD patients, particularly those that

were naïve for SARS-Cov-2 virus, generated weaker responses as compared with

healthy volunteers after this "standard" scheme of vaccination, raising question about

their actual level of protection.

The prospective observational ROMANOV-II (Response Of heModialyzed pAtieNts to

cOvid-19 Vaccination) study, aimed at comparing the severity of COVID-19 disease in

MHD patients according to their vaccination status, and at evaluating whether a 3<sup>rd</sup>

dose (3D) of BNT162b2 vaccine was safe and efficient to increase the generation of

immune effectors.

6

**Patients and methods** 

REIN Registry

The Renal Epidemiology and Information Network (REIN) is the French national

registry of all patients being treated by renal replacement therapy (15).

Clinical, demographic, and laboratory data are collected at the start of renal

replacement therapy along with dialysis modalities and are updated annually. Events

such as death, transfer, withdrawal from dialysis, placement on a transplant waiting

list, and kidney transplantation (from living or deceased donors), as well as COVID-19

diagnosis and severity are systematically reported in real time.

Interrogation of REIN registry was made on June 18th, 2021 on the period from the

February 1st to May 18th, 2021.

Severity of COVID-19 was graded as asymptomatic, mild, moderate, severe, critical or

death following the WHO recommendations (16). Because protection of a vaccine dose

was previously reported to be efficient from the tenth day following injection onward

(17), patients were considered as not vaccinated if COVID-19 infection was diagnosed

within 10 days after the first dose, and as patients of the "after 1 dose" group if the

diagnosis was made within 10 days after the second dose.

ROMANOV study population

7

According to the French health authority (18), a third vaccine injection with of mRNA

BNT162b2 COVID-19 vaccine was offered to all patients on MHD in the two centers of

Lyon University Hospital (France) that received two doses of mRNA BNT162b2 and

that did not have any of the following contra-indications: diagnosis of COVID-19 within

the last 3 months, organ transplantation within the last 3 months, Rituximab injection

within the last 3 months, ongoing flare of vasculitis, acute sepsis, major surgery within

the last 2 weeks. Before the third injection, patients were informed of their serological

status after two doses.

All adult patients who received a third vaccine injection (within 3 months after the

second vaccine injection) with BNT162b2 vaccine and gave consent for the use of their

blood were enrolled in this study. The samples were collected 10 to 14 days after the

2<sup>nd</sup> and after the 3<sup>rd</sup> vaccine injection for analysis of the post-vaccinal immune

response. This timing was selected based on previous reports demonstrating that both

cellular and antibody responses are at their peak at this time point (8).

Post-vaccinal immune responses of MHD patients were compared after 2D and 3D to

those of a cohort of healthy volunteers (HV), with blood collection at the same time

point after the 2D of BNT162b2, used as a reference.

This study was conducted in accordance with the French legislation on biomedical

research and the Declaration of Helsinki, and the protocol was evaluated by a national

ethical research committee (ID-RCB 2021-A00325-36) and registered on

clinicaltrial.gov as NCT04881396. The French national commission for the protection

of digital information (CNIL) authorized the conduction of the study.

Tolerability and Safety of vaccine injections

8

Local and systemic adverse events and use of anti-pyretic medications were collected

retrospectively, based on a self-assessment questionnaire. Data collected correspond

to adverse events within 7 days after the 2D and 3D, respectively.

As previously described (17), pain at the injection site was assessed according to the

following scale: mild, does not interfere with activity; moderate, interferes with activity;

severe, prevents daily activity; and critical, emergency department visit or hospitalization. Redness and swelling were measured according to the following scale: mild, 2.0 to 5.0 cm in diameter; moderate, >5.0 to 10.0 cm in diameter; severe, >10.0 cm in diameter; and critical, necrosis or exfoliative dermatitis (for redness) and necrosis (for swelling). Fever categories were mild, 38.0°C to 38.4°C; moderate > 38.4°C to 38.9°C; severe, >38.9°C to 40° and critical, >40°C. Medication use was not graded. Additional scales were as follows: fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain (mild: does not interfere with activity; moderate: some interference with activity; or severe: prevents daily activity), vomiting (mild: 1 to 2 times in 24 hours; moderate: >2 times in 24 hours; or severe: requires intravenous hydration), and diarrhea (mild: 2 to 3 loose stools in 24 hours; moderate: 4 to 5 loose stools in 24 hours; or severe: 6 or more loose stools in 24 hours); critical for all events indicated an emergency department visit or hospitalization.

Anti-SARS-Cov2 S-RBD humoral response assessment

9

The IgG antibodies directed against the Receptor Binding Domain (RBD) of the spike glycoprotein of the SARS-Cov2 were detected by a chemiluminescence technique, using the Maglumi® SARS-CoV-2 S-RBD IgG test (Snibe Diagnostic, Shenzen, China) on a Maglumi 2000® analyser (Snibe Diagnostic), according to the manufacturer's instructions.

Briefly, 10µL of serum were incubated in the appropriate buffer with magnetic microbeads covered with S-RBD recombinant antigen, in order to form immune complexes. After precipitation in a magnetic field and washing, ABEI (N-(4-Aminobutyl)-N-ethylisoluminol)-stained anti-human IgG antibodies were added to the samples. After a second magnetic separation and washing, the appropriate reagents

were added to initiate a chemiluminescence reaction. When necessary, sera were

diluted sequentially up to 1:1000.

As recommended by the WHO (19), the obtained titer was then expressed as binding

arbitrary units/mL (BAU/mL).

Anti-SARS-Cov2 Spike cellular response assessment

Spike specific CD4+ and CD8+ T cells responses were quantified in the circulation of

the HV and HD patients using the QuantiFERON® SARS-CoV2 test (Qiagen,

Netherlands), a commercially available Interferon Gamma Releasing Assay (IGRA),

according to the manufacturer's instructions.

Briefly, 1mL blood was distributed in each tube of the assay: (i) uncoated tube: negative

control/background noise, (ii) tube coated with mitogen: positive control, (iii) tube

coated with HLA-II restricted 13-mers peptides derived from the entire SARS-CoV2

Spike glycoprotein used to stimulate CD4+ T cells and (iv) tube coated with HLA-II and

HLA-I 8- and 13-mers derived from the entire SARS-CoV2 spike glycoprotein used to

stimulate both CD4+ and CD8+ T cells. After 20 hours of culture at 37°C, tubes were

centrifugated 15 minutes at 2500g, and stored at 4°C before INF<sub>V</sub> quantification in the

supernatant by ELISA.

The CD4+ T cell assay value was the difference between tube (iii) and the negative

control (i). The CD8+ T cell assay value was the value obtained for tube (iv), with

subtraction of the CD4 tube (iii) and the negative control (i).

Statistical analysis

10

All the analyses were carried out using R software version 4.0.4 (R Foundation for

Statistical Computing, Vienna, Austria, 2021, https://www.R-project.org) and or

GraphPad Prism v8.0 (San Diego, California USA). Categorical variables were expressed as percentages and compared with the chi-squared test. Continuous

variables were expressed as mean ± SD and compared using one-way ANOVA and

multiple t-tests post-hoc analyses or as median ± IQR and compared using Mann

Whitney test for variables with non-normal distribution.

Logistic regression models were used in both univariate and multivariate analyses. All

the explanatory variables significantly associated with outcomes in univariate analyses

(p-value < 0.10) were included in multivariate models. Stepwise regression analyses

with bidirectional elimination were then performed, using Aikake Information Criterion

to select the most fitting final multivariate models.

11

**Results** 

MHD patients are insufficiently protected against COVID-19 after 2 doses of

mRNA vaccine

In order to determine whether this observation correlated with a defective protection,

the French national registry REIN [Renal Epidemiology and Information Network (20)]

was interrogated to identify all the cases of COVID-19 diagnosed in MHD patients from

February 1<sup>st</sup> to May 18<sup>th</sup> 2021, the period during which MHD population was prioritized

for vaccination in France (Figure 1). Over these 107 days, 1474 cases of COVID-19

were reported.

12

For the 1439 (97.6%) infected MHD patients for whom the information was available,

the severity of disease was compared according to the timing of diagnosis of COVID-

19: before vaccination (not vaccinated, N=1122), 10 days after the 1st dose (after 1D,

N=192) or the 2<sup>nd</sup> dose (after 2D, N=125) of vaccine. The characteristics of the

population are presented in Table 1. Patients' characteristics were similar in the 3

groups with exception of age, cardiopathy and time in MHD, which were all three higher

in patients who developed COVID-19 after 2D of vaccine, likely because the latter were

vaccinated with the highest priority (**Table 1**).

Although the distribution of patients across the 5 stages of severity of COVID-19

defined by the WHO [Asymptomatic, Mild, Severe, Critical or Death; (21)] was

statistically different between the 3 groups (Figure 1), with an increased proportion of

less severe forms (asymptomatic or mild/moderate) of COVID-19 in vaccinated

patients, 11% of MHD patients that had received 2D of BNT162b2 vaccine died from

COVID-19 (Figure 1). The latter result is drastically different from what reported in the

pivotal studies conducted in the general population (17), and demonstrates that

vaccination with the 2D "standard" scheme is insufficient to protect all MHD patients.

As a result, France health officials authorized the administration of a 3D of vaccine in

MHD patients from mid-April 2021 onward (18).

Prospective observational study on the 3<sup>rd</sup> dose of mRNA vaccine in MHD

patients

Among the 150 MHD patients dialyzing at Lyon University Hospital, 38 (25.3%) refused

the vaccine or had contra-indications (Figure 2). Of the 112 who received 2D of

BNT162b2 mRNA vaccine, 106 gave consent for analysis of the post-vaccinal immune

response and were enrolled in ROMANOV study. In the absence of validated

correlates of vaccine-induced protection against SARS-Cov-2, we reasoned that MHD

patients would have the same level of protection than the general population (17) if

they were able to generate similar titers of anti-spike receptor binding domain (RBD)

IgG. The lowest titer observed in a cohort of 30 healthy volunteers (977 B.A.U/mL;

dashed line Figure 4A) was therefore taken as reference and response to vaccine of

MHD patients was considered optimal (n=40/106, 37.7%) or sub-optimal (n=66/106,

62.3%) depending whether the titer of anti-RBD IgG was respectively superior or equal,

or inferior to this value (Figure 2).

A 3<sup>rd</sup> dose of BNT162b2 mRNA vaccine was offered to all 66 MHD patients with

suboptimal anti-RBD IgG response and effectively administered to 56 (84.8%) of them

(**Figure 2**). In absence of clear consensus, the administration of the 3D of vaccine was

not limited to MHD patients with suboptimal anti-RBD IgG titers, and 19 (47.5%;

p<0.0001) MHD patients with optimal IgG response also accepted a 3D of vaccine

(**Figure 2**). The characteristics of the 75 MHD patients that received 3D of vaccine are

presented **Table 2**.

13

Reactogenicity to the 3<sup>rd</sup> dose of mRNA vaccine in maintenance hemodialysis

patients

Among included MHD patients, tolerability data were available for 82/106 patients after

2D and 63/75 after 3D. Overall tolerance to the 3D of BNT162b2 mRNA vaccine was

good in MHD patients (Figure 3A-B). No patients developed critical side effects

requiring hospitalization. Forty percent (25/63) developed local sides effects, the most

frequently reported being pain at the injection site (40%). Forty-six percent (29/63)

reported systemic side effects, including fatigue (32%), chills (16%) and soreness

(16%). In almost all cases (74/83, 89%) the intensity of the symptoms was mild or

moderate (Figure 3A-B).

When local and systemic side effects of vaccine were compared between 2D and 3D,

no significant difference was found, neither regarding the frequency nor severity of

symptoms (Figure 3A-B). However, when the profile of tolerance was compared

between MHD patients according to the intensity of the humoral response after 2D of

vaccine, a significant trend for more side effects was observed in patients with optimal

response (Figure 3C-D).

Impact of the 3<sup>rd</sup> dose of mRNA vaccine on humoral response of MHD patients

When the whole cohort of MHD patients (n=75) was considered, a significant increase

in the median titer of anti-RBD IgG was observed after 3D of vaccine (309.8 [36.5 -

996.3 vs 2212 [394.9 – 3247] BAU/mL after the 2D and 3D respectively; p<0.0001;

Figure 4A). This global positive result hides however major inter-individual

heterogeneity.

MHD patients with optimal humoral response after 2D of vaccine (n=19), all maintained

high levels of anti-RBD IgG after 3D but without significant increase of their titer (2724

14

[1812 – 4018] vs 3620 [2212 – 10907] BAU/mL after the 2D and 3D respectively; p=0.087; **Figure 4B**). The remaining 56 MHD patients with suboptimal humoral response after 2D were distributed into two categories: i) those with anti-RBD IgG titer below the threshold of positivity of the assay (dotted line **Figure 4A**): non responders (n=12), and ii) those with low but detectable levels of anti-RBD IgG: low responders (n=44). In contrast with MHD patients with optimal humoral response after 2D, both of the later subpopulations experienced a significant increase of anti-RBD IgG after the 3D: 217.8 [71.2 – 617.9] vs 2281 [441.4 – 2855] BAU/mL (**Figure 4C**); p<0.0001) for low responders and 0.61 [0.43 – 2.8] vs 31.5 [1.76 – 171.8] BAU/mL (**Figure 4D**; p=0.0005) for non-responders. However, 29/44 (66%) of low responders but only 1/12 (8%) of non-responders reached optimal titer of anti-RBD IgG (**Figure 4C-D**; p=0.0006). In fact, half of non-responders after 2D of vaccine remained without detectable anti-RBD IgG after 3D (6/12, 50%; **Figure 4D**), while the rest (5/12, 42%; **Figure 4D**) did develop anti-RBD IgG but at suboptimal titers.

Impact of the 3<sup>rd</sup> dose of mRNA vaccine on cellular response of MHD patients

Spike-specific T cell responses are also important components of the immune protection offered by the vaccine against SARS-Cov-2 (22). T cell responses of MHD patients after 2D of vaccine was much more heterogeneous than that of HV (**Figure 4E & Figure 4I**).

CD4+ T cells are critical to orchestrate the development of both humoral and cellular effectors. The 3D of vaccine did not result in a significant increase in spike-specific CD4+ T cells in the circulation of MHD patients neither when the amount of IFN $\gamma$ : 0.101 [0.016 - 0.856] vs 0.269 [0.030 – 0.825] I.U/mL (p=0.817) nor the proportion of MHD patients with detectable spike-specific CD4+ T cells (57% vs 64%; p=0.50) were

considered (**Figure 4E**). The result remained unchanged when the analysis was made within the subpopulations of MHD patients with optimal, low and no humoral response after 2D of vaccine (**Figure 4F-H**).

Complementing the role of antibodies, virus-specific CD8+ T cells are involved in the elimination of infected cells. In contrast with CD4+ T cells, 3D of vaccine induced a significant increase in the production of IFN $\gamma$  by spike-specific CD8+ T cells of MHD patients: 0 [0 – 0.093] vs 0 [0 - 0.206] I.U/mL (p=0.015; **Figure 4I**). Interestingly, the stronger effect was observed in the subpopulation of MHD patients with no-response after 2D of vaccine, the proportion with detectable spike-specific CD8+ T cells of which increases from 17% to 50% between 2D and 3D (p=0.09; **Figure 4J-L)** 

Defining the subpopulation of MHD patients that should receive a 3<sup>rd</sup> dose of vaccine

Because it was less well tolerated in these patients (**Figures 3C-D**) and did not improve their immune response (**Figures 4B, 4F, and 4J**), we concluded that the subpopulation of MHD patients with already optimal humoral response after 2D should not receive a 3D of vaccine.

In order to identify among the MHD patients with suboptimal response after the standard scheme of vaccination those who would benefit from 3D of vaccine, the characteristics of the MHD patients, who reached optimal titer of anti-RBD IgG and/or developed detectable levels of spike-specific CD8+ T cells after 3D (responders to 3D; n=35/56; 62.5%) were compared to that of the rest of the cohort (non-responders to 3D; n=21/56; 37.5%). The former group was younger and had developed higher titers of anti-RBD IgG and more spike-specific CD4+ T cells after 2D of vaccine (**Table 3**). In multivariate analysis, the only variable that predicted an immune response to 3D 16

was the presence of spike-specific CD4+ T cells in the circulation of MHD patients after 2D: OR = 4.80 [1.23-21.54] (p=0.029, **Table 3**). The positive and negative predictive values of the presence of spike-specific CD4+ T cells after 2D of vaccine to predict a response to 3D of vaccine were respectively 0.821 (0.721 - 0.921) and 0.571 (0.441 - 0.631), while sensibility and specificity were respectively 0.657 (0.533 - 0.781) and 0.762 (0.650 - 0.874).

**Discussion** 

18

This prospective observational study demonstrates that, in contrast with what reported in the general population (17), the "standard" 2D scheme with BNT162b2 vaccine provides insufficient protection against the severe forms of COVID-19 in MHD patients. This observation is in line with the conclusion of recent studies, which reported that MHD patients naïve for SARS-Cov-2 develop impaired humoral and cellular immune responses after 2D of BNT162b2 (9–14), and suggest that uremic toxins play a

Based on the observations that i) MHD patients with a previous history of COVID-19 had a response to vaccine indistinguishable from that of HV (9), and ii) previous studies with protein-based vaccine (such as hepatitis B vaccine) reported acceptable response rates when dosing and/or number of administrations were increased (25), a 3D of BNT162b2 vaccine was offered to MHD patients in France (18).

detrimental role on the development of adaptive immune responses (23,24).

Although, the safety of the 3D of BNT162b2 vaccine was excellent and comparable to that of the 2D with no critical local or systemic side-effect reported, the tolerance was worst in patients with already optimal humoral response, who did not improve significantly their immune response against the spike protein of SARS-Cov-2 after this additional injection. In contrast, after a 3D, 2/3 of MHD patients with suboptimal response after 2D, experienced an increase of anti-RBD-IgG titer up to optimal level and/or the appearance of spike-specific CD8+ T cells. This latter subgroup could be identified by the fact that they had developed spike-specific CD4+ T cells after 2D, a subset known to have crucial helper functions for the development of both antibodies (26) and cytotoxic T cells (27).

Based on the findings presented above, we propose the following strategy to optimize the protection of MHD patients naïve for SARS-Cov-2. All these vulnerable patients should be offered the standard scheme of vaccination in priority. Anti-RBD IgG and spike-specific CD4+ T cells should be measured in their circulation 10 to 14 days after 2D, resulting in the definition of 3 subgroups with distinct needs: i) patients with optimal anti-RBD IgG titer do not require further intervention, ii) patients with suboptimal anti-RBD IgG titer but detectable spike-specific CD4+ T cells, whom are the most likely to respond, should be offered a 3D of vaccine, and iii) patients with suboptimal anti-RBD IgG titer but no detectable spike-specific CD4+ T cells after 2 doses, in which the 3D of vaccine is unlikely to be sufficient, might rather be listed to receive infusion of monoclonal antibodies as a mean to induce passive immunization.

## **Disclosers**

All authors declared no conflicts of interest.

## References

- 1. Thaunat O, Legeai C, Anglicheau D, Couzi L, Blancho G, Hazzan M, et al. IMPact of the COVID-19 epidemic on the moRTAlity of kidney transplant recipients and candidates in a French Nationwide registry sTudy (IMPORTANT). Kidney Int. 2020 Dec;98(6):1568–77.
- 2. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020 Aug;584(7821):430–6.
- 3. Quintaliani G, Reboldi G, Di Napoli A, Nordio M, Limido A, Aucella F, et al. Exposure to novel coronavirus in patients on renal replacement therapy during the exponential phase of COVID-19 pandemic: survey of the Italian Society of Nephrology. J Nephrol. 2020 Aug;33(4):725–36.
- 4. Ng JH, Hirsch JS, Wanchoo R, Sachdeva M, Sakhiya V, Hong S, et al. Outcomes of patients with end-stage kidney disease hospitalized with COVID-19. Kidney Int. 2020 Dec;98(6):1530–9.
- 5. Jager KJ, Kramer A, Chesnaye NC, Couchoud C, Sánchez-Álvarez JE, Garneata L, et al. Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. Kidney Int. 2020 Dec;98(6):1540–8.
- 6. Hilbrands LB, Duivenvoorden R, Vart P, Franssen CFM, Hemmelder MH, Jager KJ, et al. COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration. Nephrology Dialysis Transplantation. 2020 Nov 1;35(11):1973–83.
- 7. Vaccins Covid-19: quelle stratégie de priorisation à l'initiation de la campagne ? [Internet]. Haute Autorité de Santé. [cited 2021 Apr 2]. Available from: https://www.has-sante.fr/jcms/p\_3221237/fr/vaccins-covid-19-quelle-strategie-de-priorisation-a-l-initiation-de-la-campagne
- 8. Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, et al. COVID-19 vaccine BNT162b1 elicits human antibody and T H 1 T cell responses. Nature. 2020 Oct;586(7830):594–9.
- 9. Espi M, Charmetant X, Barba T, Koppe L, Pelletier C. Impaired humoral and cellular immune responses to SARS-Cov-2 mRNA vaccine in naïve maintenance hemodialysis patients: the ROMANOV study. Kidney Int. 2021
- Bertrand D, Hamzaoui M, Lemée V, Lamulle J, Hanoy M, Laurent C, et al. Antibody and T Cell Response to SARS-CoV-2 Messenger RNA BNT162b2 Vaccine in Kidney Transplant Recipients and Hemodialysis Patients. J Am Soc Nephrol. 2021 Jun 10;ASN.2021040480.
- 11. Danthu C, Hantz S, Dahlem A, Duval M, Ba B, Guibbert M, et al. Humoral Response after SARS-Cov-2 mRNA Vaccine in a Cohort of Hemodialysis Patients

- and Kidney Transplant Recipients. J Am Soc Nephrol. 2021 Jun 16;ASN.2021040490.
- 12. Speer C, Göth D, Benning L, Buylaert M, Schaier M, Grenz J, et al. Early Humoral Responses of Hemodialysis Patients after COVID-19 Vaccination with BNT162b2. Clin J Am Soc Nephrol. 2021 May 24;CJN.03700321.
- 13. Grupper A, Sharon N, Finn T, Cohen R, Israel M, Agbaria A, et al. Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis. Clin J Am Soc Nephrol. 2021 Apr 6;CJN.03500321.
- 14. Rincon-Arevalo H, Choi M, Stefanski A-L, Halleck F, Weber U, Szelinski F, et al. Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. Sci Immunol. 2021 Jun 15;6(60):eabj1031.
- Couchoud C, Stengel B, Landais P, Aldigier J-C, de Cornelissen F, Dabot C, et al. The renal epidemiology and information network (REIN): a new registry for end-stage renal disease in France. Nephrol Dial Transplant. 2006 Feb;21(2):411– 8.
- COVID-19 Clinical management: living guidance [Internet]. [cited 2021 Jun 25].
   Available from: https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-clinical-2021-1
- 17. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine. 2020 Dec 10;0(0):null.
- 18. dgs\_urgent\_52\_precisions\_sur\_la\_vaccination\_imd.pdf [Internet]. [cited 2021 May 17]. Available from: https://solidarites-sante.gouv.fr/IMG/pdf/dgs\_urgent\_52\_precisions\_sur\_la\_vaccination\_imd.pdf
- 19. Mattiuzzo G, Bentley EM, Hassall M, Routley S, Bernasconi V, Kristiansen P, et al. Establishment of the WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody. :60.
- 20. R.E.I.N. (Réseau Epidémiologique et Information en (…) Agence de la biomédecine [Internet]. 2021 [cited 2021 Jun 25]. Available from: https://www.agence-biomedecine.fr/R-E-I-N-Reseau-Epidemiologique-et-Information-en-Nephrologie
- 21. Clinical Spectrum [Internet]. COVID-19 Treatment Guidelines. [cited 2021 Jun 25].

  Available from: https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/
- 22. Chen Z, John Wherry E. T cell responses in patients with COVID-19. Nat Rev Immunol. 2020 Sep;20(9):529–36.

- 23. Espi M, Koppe L, Fouque D, Thaunat O. Chronic Kidney Disease-Associated Immune Dysfunctions: Impact of Protein-Bound Uremic Retention Solutes on Immune Cells. Toxins. 2020 May;12(5):300.
- 24. Betjes MGH. Immune cell dysfunction and inflammation in end-stage renal disease. Nat Rev Nephrol. 2013 May;9(5):255–65.
- 25. Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep. 2006 Dec 8;55(RR-16):1–33; quiz CE1-4.
- 26. Chen C-C, Koenig A, Saison C, Dahdal S, Rigault G, Barba T, et al. CD4+ T Cell Help Is Mandatory for Naive and Memory Donor-Specific Antibody Responses: Impact of Therapeutic Immunosuppression. Front Immunol. 2018;9:275.
- 27. Bevan MJ. Helping the CD8 + T-cell response. Nat Rev Immunol. 2004 Aug;4(8):595–602.

**Acknowledgements** 

The authors are indebted to the members of the GRoupe de REcherche Clinique

(GREC: Céline Dagot, Farah Pauwels, Fatiha M'Raiagh and Daniel Sperandio), and

Lise Siard, Claudine Lecuelle, and Philippe Favre from Eurofins Biomnis for their

precious help during the conduction of the study.

ME is supported by the Hospices civils de Lyon (année médaille d'or) and by INSERM

(Poste accueil). XC is supported by the Société Française de Transplantation. OT is

supported by Fondation pour la Recherche Médicale (PME20180639518) and the

"Etablissement Français du Sang".

ME, XC, TB, EM and OT are members of the Lyon Immunopathology Federation (LIFe)

of the Hospices Civils de Lyon.

24

## **Tables**

**Table 1 –** Characteristic of COVID-19 infected MHD patients, according to their vaccination status.

Variables N (%) or mean ±SD	Whole cohort N=1439	Not vaccinated N=1122	After 1D N=192	After 2D N=125	р
Sexe ratio (M/F)	1.37 (833/606)	1.32 (639/483)	1.49 (115/77)	1.72 (79/46)	0.338
Age (years)	69.6± 15.0	68.5± 15.2	71.7± 14.3	74.0± 13.5	<0.0001
BMI (kg/m²)	27.4± 6.30	27.5± 6.24	27.0± 6.48	27.3± 6.52	0.676
Comorbidities					
Diabetes	732 (51)	581 (52)	89 (46)	62 (50)	0.364
Cardiopathy	572 (40)	420 (37)	84 (44)	68 (54)	0.0006
Vascular disease	380 (26)	280 (25)	58 (30)	42 (34)	0.051
Respiratory disease	269 (19)	204 (18)	42 (22)	23 (18)	0.477
Malignancy	148 (10)	108 (10)	25 (13)	15 (12)	0.289
HD parameters					
Time in HD (months)	5.5 ±6.6	5.2 ±6.2	6.4 ±7.7	6.0 ±7.6	0.046
Time HD/week (hours)	11.6 ±1.63	11.6 ±1.62	11.8 ±1.70	11.7 ±1.60	0.196

**Abbreviations are**: BMI, body mass index; MHD, maintenance hemodialysis; Not vaccinated: diagnosis of COVID-19 in not vaccinated patients and diagnosis in the first 10 days following the 1st dose; After 1 dose: diagnosis of COVID-19 at least 10 days after the 1st doses, and in the first 10 days following the 2nd dose; After 2 doses: diagnosis of COVID-19 at least 10 days after the 2nd dose.

**Table 2 –** Clinical and biological characteristic of MHD patients injected with a 3<sup>rd</sup> dose of BNT162b2.

Variables	Whole cohort	
N (%) or mean ±SD	N=75	
Males	48 (64)	
Age (years)	65.8± 14.4	
BMI (kg/m²)	26.8± 6.4	
Comorbidities		
Diabetes	35 (47)	
Cardiopathy	36 (48)	
Respiratory disease	6 (8)	
Hepatic disease	4 (5)	
Cause of renal failure		
Vascular	17 (23)	
Diabetes	27 (36)	
Glomerulonephritis	7 (9)	
Hereditary	3 (4)	
Uropathy	0 (0)	
Others	21 (28)	
Previous SOT	16 (21)	
IS therapy	8 (11)	
History of COVID-19	3 (4)	
Time in HD (months)	56± 69	
HD parameters		
Time HD/week (hours)	10.6± 2.77	
Kt/V	1.56± 0.43	
Biological characteristics		
Hemoglobinemia (g/L)	106± 16	
C reactive protein (mg/L)	13.4± 20.9	
Albuminemia (g/L)	36.4± 6.7	

**Abbreviations are**: BMI, body mass index; OR, odd ratio; Cl95%, 95% confident interval; SOT, solid organ transplantation; IS, immunosuppressive; HD, hemodialysis; Kt/V was used for the quantification of dialysis adequacy by the formula: dialysis clearance of urea (K) multiplied by t (dialysis time) divided by the volume of distribution of urea (V); CRP, c reactive protein.

**Table 3 –** Uni and multivariate analysis used to identify predictors of an immunological response (i.e optimal humoral response or apparition of CD8+ response) after the 3<sup>rd</sup> dose).

Variables N (%) or mean (±SD)	Non-Resp 3D N=21	Resp 3D N=35	OR univariate (Cl <sub>95%</sub> , p)	OR multivariate (Cl <sub>95%</sub> , p)
Males	16 (76)	23 (66)	0.60 (0.16-1.97, p=0.411)	
Age (years)	71.7± 12	65.3± 14	0.96 (0.92-1.00, p=0.089)	0.96 (0.91–1.01, p=0.135)
BMI (kg/m²)	25.6± 5.1	27.7± 6.9	1.07 (0.97-1.20, p=0.239)	
Comorbidities				
Diabetes	9 (43)	19 (54)	1.58 (0.53-4.82, p=0.409)	
Cardiopathy	13 (62)	16 (46)	0.52 (0.17-1.54, p=0.243)	
Respiratory disease	2 (10)	2 (6)	0.58 (0.06-5.12, p=0.596)	
Hepatic disease	2 (10)	2 (6)	0.58 (0.06-5.12, p=0.596)	
Previous SOT	4 (19)	5 (Ì4́)	0.71 (0.17-3.20, p=0.640)	
IS therapy	2 (10)	6 (17)	1.97 (0.40-14.4, p=0.436)	
History of COVID-19	1 (5)	2 (6)	1.21 (0.11-27.1, p=0.878)	
Time in HD (days)	1298± 1064	1153± 1454	1.00 (1.00-1.00, p=0.690)	
HD parameters			, , ,	
Time HD/week (hours)	676± 103	688± 74	1.00 (1.00-1.01, p=0.592)	
Kt/V	1.5± 0.3	1.4± 0.5	0.62 (0.15-2.29, p=0.484)	
Biological			, , ,	
Hemoglobinemia (g/L)	108± 10.1	107± 15.1	0.99 (0.95-1.04, p=0.764)	
C reactive protein (mg/L)	12.5± 17.5	14.4± 24.3	1.00 (0.98-1.04, p=0.743)	
Albuminemia (g/L)	34.8± 4.5	36.2± 5.7	1.05 (0.95-1.17, p=0.336)	
Anti SARS-Cov-2			,	
response after 2 doses				
Antibody titer	35± 50	74± 73	1.01 (1.00-1.02, p=0.045)	1.00 (0.99-1.02, p=0.507)
CD4+ response	5 (24)	23 (66)	6.13 (1.91-22.7, p=0.004)	4.80 (1.23-21.5, p=0.029)
CD8+ response	4 (19)	15 (43)	3.19 (0.95-12.8, p=0.076)	,

Abbreviations are: Non-Resp, patients without optimal humoral response after the 3<sup>rd</sup> dose neither apparition of CD8+ response; Resp, patients with optimal humoral response or apparition of CD8+ response; BMI, body mass index; OR, odd ratio; CI95%, 95% confident interval; SOT, solid organ transplantation; IS, immunosuppressive; HD, hemodialysis; Kt/V was used for the quantification of dialysis adequacy by the formula: dialysis clearance of urea (K) multiplied by t (dialysis time) divided by the volume of distribution of urea (V); CRP, c reactive protein.

Figure legends

Figure 1 – Severity of COVID-19 disease in MHD patients according to their

vaccination status

Severity of COVID-19 was color coded and the distribution was compared between the

groups of MHD patients defined according to their vaccination status. Chi-square test.

Figure 2 – Flow chart of the ROMANOV study

Figure 3 - Reactogenicity to the 3rd dose of mRNA vaccine in MHD patients

A/ Proportion of MHD patients who developed local and systemic adverse events after

2D and after 3D dose of vaccine are represented. Severity of the adverse event is

color-coded (0-4) according to the scale detailed in the material and method section.

B/ The number and the severity of local and systemic adverse events that occurred

after 2D and 3D of vaccine are compared. Chi-square test.

C/ Proportion of MHD patients who developed local and systemic adverse events after

3D of vaccine according to their humoral status after the 2<sup>nd</sup> injection. Optimal (Opt):

same titer than healthy volunteers vs sub-optimal (S-Opt): lower titer than healthy

volunteers.

D/ The number and the severity of local and systemic adverse events that occurred

after 2D and 3D are compared. Chi-square test.

The number and the severity of local and systemic adverse events that occurred after

3D of vaccine were compared between Opt and S-Opt patients. Chi square test.

28

**Abbreviations are:** ns, p non-significant; \*\*\*, p<0.0001.

Figure 4 – Evolution of immune effectors numbers between 2D and 3D of vaccine

in MHD patients

Immune effectors directed against the spike protein of SARS-Cov-2 were quantified in

30 healthy volunteers (open triangles) after 2D of vaccine and in 75 MHD patients

(open circles) after the 2D and 3D of vaccine.

**A-D/** Anti RBD-IgG titers expressed in binding arbitrary units (BAU/mL). Upper dashed

line represents the lowest value observed in healthy volunteers after the standard (2

doses) scheme of vaccination and define the threshold for optimal response. MHD

patients with sub-optimal response after 2D of vaccine were further divided into non-

responders and low responders, depending whether anti RBD-lgG titer was

respectively below or above the threshold of positivity (dotted line) of the assay (4A).

Evolution of anti RBD-lgG titers between the 2D and 3D of vaccine were compared in

optimal responders (n=19, 4B), low responders (n=44, 4C) and non-responders (n=12,

4D). Wilcoxon test.

**E-H/** Secretion of interferon gamma by circulating spike-specific CD4+ T cells (**4E**).

The proportion of MD patients with spike-specific CD4+ T cells were compared

between the 2D and 3D of vaccine for optimal- (4F), low- (4G), and non-responders

(4H). Chi square test.

I-L/ Secretion of interferon gamma by circulating spike- specific CD8+ T cells (41). The

proportion of MD patients with spike-specific CD8+ T cells were compared between

the 2D and 3D of vaccine for optimal- (4F), low- (4G), and non-responders (4H). Chi

square test.

29

**Abbreviations are:** ns, p non-significant; \*\*\*\*, p<0.0001.

Figure 1




Figure 2




Figure 3




Figure 4

